![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The Phase II clinical trial will evaluate the efficacy of a single dose regimen of Travelan® in a controlled human infection model (CHIM) using the enterotoxigenic Escherichia coli (ETEC) strain H10407.
Lead Product(s): Bovine Colostrum
Therapeutic Area: Infections and Infectious Diseases Product Name: Travelan
Highest Development Status: IND EnablingProduct Type: Large molecule
Recipient: Immuron
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement October 04, 2022
Details:
OLX703A utilizes GalNAc-asiRNA technology and is designed to inhibit all HBV transcripts and proteins, including hepatitis B surface antigen (HBsAg).
Lead Product(s): OLX703A
Therapeutic Area: Infections and Infectious Diseases Product Name: OLX703A
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: OliX Pharmaceutical
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement October 20, 2021